HOME >> BIOLOGY >> NEWS
Diagnostic breakthrough for Burkitt lymphoma reported in NEJM

An international research study involving the University of Nebraska Medical Center, the National Cancer Institute and 10 other institutions has successfully identified the gene expression signature for Burkitt lymphoma. The discovery, which is reported in the June 8 edition of The New England of Medicine, will allow physicians to better diagnose and treat Burkitt lymphoma and better distinguish it from another more common form of malignant lymphoma.

Burkitt lymphoma is a rare aggressive B cell lymphoma that accounts for 30 to 50 percent of lymphomas in children but only 1 to 2 percent of lymphomas in adults. Burkitt lymphoma is rapidly fatal if untreated, but it is curable with intensive therapy.

Burkitt lymphoma features a high degree of proliferation of the malignant cells and deregulation of the c-myc gene, which is characteristic of Burkitt lymphoma. The distinction between Burkitt lymphoma and diffuse large B cell lymphoma (DLBCL), the most common form of non-Hodgkin's lymphoma in adults, is critical, because the management of these two diseases differs. About 300 new cases of Burkitt lymphoma, typically in children, are diagnosed in the U.S. each year.

Whereas a relatively low-dose chemotherapy regimen is typically used to treat DLBCL, this regimen is inadequate for Burkitt lymphoma, which requires intensive chemotherapy. In addition, because of the high risk of central nervous system involvement with Burkitt lymphoma, it is essential that intrathecal or systemic chemotherapy that crosses the blood-brain barrier be administered. This type of chemotherapy is unnecessary in most cases of DLBCL.

The article in The New England Journal of Medicine featured the results of two studies on the molecular diagnosis of Burkitt lymphoma involving several European and North American institutions. One of the research teams was led by Wing (John) Chan, M.D., the Amelia and Austin Vickery Professor of Pathology and co-director of the Center for Lym
'"/>

Contact: Tom O'Connor
toconnor@unmc.edu
402-559-4690
University of Nebraska Medical Center
9-Jun-2006


Page: 1 2

Related biology news :

1. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
2. Almac Diagnostics attends pre-IDE meeting with FDA
3. Almac Diagnostics announces pioneering genetic research on colorectal pre-malignancies
4. 2007 EURYI: 20 young researchers to receive Nobel Prize-sized awards for breakthrough ideas
5. Major breakthrough in understanding how HIV interferes with infected cell division
6. Variant CJD -- Prion amplification breakthrough brings new insights and hopes for a blood test
7. Cloned pigs help scientists towards a breakthrough in Alzheimers
8. Biotech breakthrough could end biodiesels glycerin glut
9. Digestive Disease Week 2007 spotlights breakthrough research in digestive health
10. Stanford scientists make major breakthrough in regenerative medicine
11. Research on grey mold offers possible breakthrough in tomato cultivation

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Diagnostic breakthrough for Burkitt lymphoma reported NEJM

(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
(Date:6/24/2015)... YORK , June 24, 2015 This ... market, over the next six years. It contains an ... the industry, along with their impact from the short, ... It also discusses the industry, market, and technology trends ... that the need of concerned authorities to efficiently manage ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
(Date:7/1/2015)... Calif. , July 1, 2015   ... on the development of groundbreaking drugs to treat ... announced today that Robert G. Miller , ... at Sutter Health,s California Pacific Medical Center in San ... ALS Association for $1.5 million to help fund ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Apex Therapeutics ... BIO International Convention in Philadelphia, PA. , The presentation took place on ... outlined the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)... ... 30, 2015 , ... uBiome and OpenBiome Partner for Microbiome ... fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome and OpenBiome ... microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. diff). , ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
Cached News: